The company is already engaged with pharmaceutical and biotech companies to help support them to accelerate the development of effective new drugs and treatments for Alzheimer’s Disease. The company will develop its technology with the aim of enabling doctors to catch the condition years earlier than is possible with current diagnostic methods, and to help patients in all corners of the world.
Alzheimer’s Disease is the most common form of dementia and presents an urgent challenge in a world of ageing populations and rising healthcare costs. Globally, the number of people living with dementia will increase from 50 million in 2018 to 152 million in 2050 (Source: Dementia fact sheet December 2017; World Health Organisation.) Currently, diagnosis is possible only after symptoms such as memory loss occur; unfortunately, by this point changes to the brain have already taken place which will make treatments less effective.
Read more (University of Oxford website)